Results 51 to 60 of about 9,997 (164)

Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice

Patient Preference and Adherence, 2013
Secundino López-Pousa,1 Francisco Javier Arranz21Unit for Assessment of Memory and Dementia, Institut d’Assistència Sanitària de Girona, Salt, Girona, 2CNS Area, Medical Department and Health Innovation, Esteve,
López-Pousa S, Arranz FJ
doaj  

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

Dementia and Geriatric Cognitive Disorders Extra, 2011
Background: As of 2010, the rivastigmine patch was licensed for the treatment of Alzheimer’s disease (AD) in 64 countries. Methods: This 24-week, multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy, safety and ...
Yu Nakamura, Yukimichi Imai, Masahiro Shigeta, Ana Graf, Toru Shirahase, Hyosung Kim, Akifumi Fujii, Joji Mori, Akira Homma   +8 more
doaj   +1 more source

Design, Synthesis, X‐Ray Crystallographic Characterization, Anticholinesterase and Antioxidant Evaluation, and Molecular Modeling of Novel Dispiroindene‐Pyrrolidine Derivatives as Multifunctional Anti‐Alzheimer Agents

Drug Development Research, Volume 87, Issue 5, August 2026.
ABSTRACT A novel series of 5‐chloro‐N‐alkyl‐1′,1″‐dimethyl‐4′‐aryldispiro[indene‐2,3′‐pyrrolidine‐2′,3″‐indoline]−1,2″(3H)‐diones (4a–r) was rationally designed and synthesized via a one‐pot multicomponent reaction of N‐alkylated 5‐chloroisatin derivatives, 2‐(arylmethylidene)−2,3‐dihydro‐1H‐inden‐1‐ones (2a–i), and sarcosine (3).
Aisha A. Alsfouk, Riham A. El‐Shiekh, Benson M. Kariuki, Eman Sabry, Mohamed G. Abouelenein, Asmaa Saleh, Mahmoud G. A. Saleh, Aladdin M. Srour   +7 more
wiley   +1 more source

The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na+, K+)-, Mg2+-ATPase activities, antioxidant status, and learning performance of aged rats

Neuropsychiatric Disease and Treatment, 2008
Haris Carageorgiou1, Antonios C Sideris1, Ioanna Messari1, Chrissoula I Liakou1, Stylianos Tsakiris21Department of Pharmacology, 2Department of Physiology, Medical School, University of Athens, Athens, GreeceAbstract: We investigated the effects of ...
Haris Carageorgiou, Antonios C Sideris, Ioanna Messari, Chrissoula I Liakou, Stylianos Tsakiris   +4 more
doaj  

Dementia Risk With Combined Statin and Antihypertensive Drugs That Increase Versus Decrease Angiotensin‐II Formation: Findings From the 45 and Up Study

International Journal of Geriatric Psychiatry, Volume 41, Issue 8, August 2026.
ABSTRACT Background Hypertension and dyslipidaemia are key modifiable risk factors of dementia, and the combined use of statins and antihypertensive medications (AHMs) may offer protective benefits. However, evidence on specific combinations remains limited.
Eyayaw Ashete Belachew, Gregory M. Peterson, Mohammed S. Salahudeen, Woldesellassie M. Bezabhe   +3 more
wiley   +1 more source

Effects of rivastigmine on gait in patients with neurodegenerative disorders: A systematic review and meta-analysis.

PLoS ONE
Background & aimsGait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and higher-level gait disorders, which are associated with cholinergic deficits.
Sung Ryul Shim, Jong-Yeup Kim, Kyum-Yil Kwon, Jieun Shin, Yungjin Lee, Seon-Min Lee   +5 more
doaj   +1 more source

Hypotensive Episodes Precede Cognitive Fluctuations in Parkinson's Disease Dementia

Movement Disorders Clinical Practice, Volume 13, Issue 8, Page 1967-1971, August 2026.
Abstract Background Cognitive fluctuations (CFs) are a disabling feature in Parkinson's disease dementia (PDD) and contribute to caregiver burden. The relationship between CFs and neurogenic orthostatic hypotension (nOH), a common autonomic complication in PDD, has not been adequately examined.
Jorge Patino, Kevin Duque, Jesus Abanto, Aaron Bloemer, Heba Deraz, Alberto J. Espay, Abhimanyu Mahajan   +6 more
wiley   +1 more source

Rivastigmine in Chinese patients with subcortical vascular dementia

Neuropsychiatric Disease and Treatment, 2007
Vincent Mok1, Adrian Wong1, Simon Ho2, Thomas Leung1, Wynnie WM Lam2, Ka Sing Wong11Department of Medicine and Therapeutics; 2Department of Radiology and Organ Imaging, The Chinese University of Hong Kong, Shatin, Hong Kong, ChinaBackground: We explored ...
Vincent Mok, Adrian Wong, Simon Ho, Thomas Leung, Wynnie WM Lam, et al   +5 more
doaj  

EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE

Acta Medica Iranica, 2008
Alzheimer's disease is the most common degenerative disease of brain. Nowadays, the most common treatment being used to slow down disease progression, include Donepezil , Rivastigmine and Galantamine, which all of them act as inhibitors of acetyl ...
R. Abolfazli, S. Ghazanshahi M. Nazeman   +1 more
doaj  

Effects of Two-Year Treatment with the Cholinesterase Inhibitor Rivastigmine on Behavioural Symptoms in Alzheimer’s Disease

Behavioural Neurology, 1999
Alzheimer’s disease (AD) is accompanied by prominent behavioural disturbances. They cause significant distress for both caregivers and patients and can play a major role in the decision to institutionalise AD patients.
Michael Rösler, Wolfgang Retz, P. Retz-Junginger, Hans Joachim Dennler   +3 more
doaj   +1 more source